Short communication two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese

Drug Metabolism and Disposition

Volumn 37, Issue 4, 2009, Pages 699-701

  Matsunaga, Masayuki ^a,b   Yamazaki, Hiroshi ^a   Kiyotani, Kazuma ^a   Iwano, Shunsuke ^a   Saruwatari, Jyunji ^c   Nakagawa, Kazuko ^c   Soyama, Akiko ^d   Ozawa, Shogo ^d   Sawada, Jun Ichi ^d   Kashiyama, Eiji ^b   Kinoshita, Moritoshi ^b   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYDEXTROMETHORPHAN; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DEMETHYLATION; ENZYME KINETICS; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; JAPANESE; LIVER MICROSOME; METABOLISM; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ENZYMOLOGY; GENETICS; JAPAN;

ESCHERICHIA COLI;

CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; HAPLOTYPES; HUMANS; JAPAN; MICROSOMES, LIVER; PHENOTYPE;

EID: 63849149891     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.026096     Document Type: Article

References (10)

1. 120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. Biochem J 380:353-360.
2. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
3. Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, and Kamataki T (1998) High catalytic activity of human cytochrome P450 co-expressed with human NADPH- cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 55:1315-1325.
4. Johansson I, Lundqvist E, Dahl ML, and Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355.
5. Nakamura K, Ariyoshi N, Yokoi T, Ohgiya S, Chida M, Nagashima K, Inoue K, Kodama T, Shimada N, and Kamataki T (2002) CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem Biophys Res Commun 293:969-973.
6. Ramamoorthy Y, Tyndale RF, and Sellers EM (2001) Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11:477-487.
7. Soyama A, Kubo T, Miyajima A, Saito Y, Shiseki K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Tomoike H, et al. (2004) Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene. Drug Metab Pharmacokinet 19:313-319.
8. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, and Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570-575.
9. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, and Kamataki T (2004) CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 19:120-129.
10. Yamazaki H, Kiyotani K, Tsubuko S, Matsunaga M, Fujieda M, Saito T, Miura J, Kobayashi S, and Kamataki T (2003) Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab Pharmacokinet 18:269-271.